Bli medlem
Bli medlem

Du är här


Vigmed: Vigmed Holding AB publishes Financial Objectives

Vigmed has recently launched its first commercially available product
line, CLiP®, to the European market. The launch of a second product
line, SWiNG, will follow during the second half of 2014. As the
Company now enters into a commercialization phase, the Board of
Directors has decided to submit a first public insight into the
Financial Objectives of Vigmed Holding AB.

When evaluating the Financial Objectives of Vigmed given below, its
vital to understand the assumptions behind the figures, these are;
(1) only product lines within the CLiP® and SWiNG brands plus the
third product line to be produced at AMB Industri AB from 2015/16 are
included in the calculations, (2) the only markets included are those
of Europe and the Americas, (3) market launches will take place as

It should be noted that Vigmed during the period in question also
intends to launch additional product lines and introduce its products
to markets such as China and other Countries. Financial contributions
from these areas have not been included in the Financial Objectives
presented now.

Based on the assumptions given above Vigmed, has a Financial Objective
to deliver a Net Revenue of SEK 400-600 million in 2018 with a margin
level of Earnings before Tax (EBT) of 13-17%. The more traditional
measurement of EBIT is somewhat less relevant for Vigmed considering
its chosen business model of controlled outsourcing of manufacturing
and distribution (for further information see
(, slide

For the start-up year of 2014 Vigmed expects to reach a Net Revenue of
SEK 5-10 million with a negative Result and Cash-flow.

For further information contact:

Chairman of the board, Lennart Holm +46 70-630 8562 or CEO, Finn
Ketler +46 42 600 5311

Vigmed is a Swedish medical technology company whose mission is to
eliminate needlestick injuries by offering the market unique
needle-protected products. Vigmed is headquartered in Helsingborg,
Sweden, and has approximately 15 employees. Vigmed's share is traded
on NASDAQ OMX First North in Stockholm (ticker VIG) and has

5 400 shareholders. Remium Nordic AB is the Company's Certified

Additional information such as company description, a video
presentation and risk factors can be found on Vigmed's website:


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.